Clinical trials: Influenza Type B
Influenza
Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)
To assess whether CAIV-T was transmitted from vaccinated children to their unvaccinated contacts in a day care setting; and if so, to estimate the rate of transmission.
- Trial name
- NCT00192361
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers…
- Trial name
- NCT00192283
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 2,903 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Diphtheria, Acellular Pertussis
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules
In this study, infants who were previously vaccinated with hepatitis B vaccine at birth will be randomly allocated into two groups: one group of subjects will receive diphtheria, tetanus, acellular pertussis- hepatitis B…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus, Haemophilus Influenzae Type b
- Trial name
- NCT00316147
- Testing
- DTPa-HBV-IPV/Hib vaccine
- Where
- 4 sites in India
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of(CAIV-T) in Healthy Children.
- Trial name
- NCT00192374
- Testing
- CAIV-T, Liquid
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 1,920 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B
Each winter, viruses belonging to two kinds of influenza A ("A/H1N1" \& "A/H3N2") and two kinds of influenza B ("B/Yamagata" \& "B/Victoria") can cause illness.
- Trial name
- TITRE II (NCT01067404)
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 3 sites in Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- British Columbia Centre for Disease Control
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Diphtheria, Tetanus
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks
A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02257645
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Haemophilus Influenza
A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine
Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children.
- Trial name
- NCT02692859
- Testing
- Hib conjugate vaccine
- Volunteers
- 1,992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Diphtheria, Tetanus
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRP~T combined vaccine with Tritanrix-HepB/Hib™, when both are given concomitantly with OPV at 6, 10, and 14 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00348881
- Testing
- DTaP-HB-PRP~T combined vaccine, Tritanrix-HepB/Hib™ vaccine, Oral poliomyelitis vaccine (OPV)
- Where
- 4 sites in Philippines
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Influenza A
MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study
The purpose of this study is to evaluate the usability of the MGC Health COVID-19 \& Flu A+B Home Multi Test in home use.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT05732610
- Testing
- MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical Group Care, LLC
Chronic Lymphocytic Leukemia
Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients
The purpose of the study is to determine whether it is possible to improve the immune response rate to 'flu vaccination in patients with chronic lymphocytic leukaemia (CLL).
- Trial name
- CLLIFVAC (NCT00596336)
- Testing
- Imiquimod cream, influenza vaccine
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The Royal Bournemouth Hospital
Haemophilus Influenza Type b
Exploratory Clinical Study of MT-2301
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
- Trial name
- NCT02140047
- Testing
- Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, Haemophilus influenza type b conjugate vaccine + DPT-IPV
- Where
- Japan
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Subjects Possibly Exposed to COVID-19
Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program
We are trying to see whether a self-collected saliva swab in the home setting is as good as or better than a study clinician-collected anterior nose swab in evaluating whether you are positive for COVID-19 or Influenza…
- Trial name
- NCT04681950
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Biocerna LLC
Haemophilus Influenzae Type B, Carrier State
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated.
- Trial name
- NCT00153556
- Testing
- Hib conjugate vaccine (HbOC, Wyeth Vaccines)
- Where
- United States
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Healthy
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.
- Trial name
- NCT00192400
- Testing
- CAIV-T
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
This study is designed as a prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05163730
- Testing
- COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 2,472 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Diagnostics Jena GmbH
Influenza
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist…
- Trial name
- NCT00192491
- Testing
- FluMist
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
To describe the safety findings from Days 0 to 44 following injection of the 2003-2004 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule in accordance with the…
- Trial name
- NCT00836953
- Testing
- Influenza virus vaccine (Pediatric formulation)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of the 2012/2013 seasonal influenza DNA vaccine (HA DNA)…
- Trial name
- NCT01609998
- Testing
- Seasonal Influenza DNA vaccine, TIV
- Where
- 5 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, Influenza a
Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza a, Influenza Type B, Influenza Viral Infections
- Trial name
- NCT06622590
- Testing
- QIV, QIV control
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences